Heli Malm

Dr. Heli Malm


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2016 in Journal of the American Academy of Child & Adolescent Psychiatry
Verified
Journal Article
Closed access
HMHeli Malm
Heli Malm
ABAlan S. Brown
Alan S. Brown
MGMika Gissler
Mika Gissler
DGDavid Gyllenberg
David Gyllenberg
SHSusanna Hinkka-Yli-Salomäki
Susanna Hinkka-Yli-Salomäki
ASAndre Sourander
Andre Sourander

1 July 2011 in Obstetrics & Gynecology
Verified
Journal Article
Closed access
HMHeli Malm
Heli Malm
MAMiia Msc Artama
Miia Msc Artama
MGMika MSocSc Gissler
Mika MSocSc Gissler
ARAnnukka Ritvanen
Annukka Ritvanen
OBJECTIVE: To estimate the risk of major congenital anomalies after exposure to selective serotonin reuptake inhibitors during pregnancy. METHODS: A retrospective cohort study based on national population-based registers (years 1996–2006) of births, congenital anomalies, and terminations of pregnancy because of severe fetal anomalies (maintained by National Institute for Health and Welfare, source offspring population n=635,583) and drug reimbursements (Social Insurance Institution) linked by a personal identification number. Offspring exposed to selective serotonin reuptake inhibitors during the first trimester (n=6,976) were compared with unexposed referent offspring. RESULTS: Overall major congenital anomalies were not more common in selective serotonin reuptake inhibitor-exposed offspring compared with unexposed referent offspring (adjusted odds ratio [OR] 1.08, 95% confidence interval [CI] 0.96–1.22). Fluoxetine was associated with an increased risk of isolated ventricular septal defects (adjusted OR 2.03, 95% CI 1.28–3.21) and paroxetine was associated with an increased risk of right ventricular outflow tract defects (adjusted OR 4.68, 95% CI 1.48–14.74). Citalopram use was associated with neural tube defects (adjusted OR 2.46, 95% CI 1.20–5.07). Fetal alcohol spectrum disorders were 10-times more common in the selective serotonin reuptake inhibitor-exposed offspring than in unexposed referent offspring. CONCLUSION: Fluoxetine use is associated with an increased risk of isolated ventricular septal defects and paroxetine is associated with right ventricular outflow tract defects. The absolute risk for these specific cardiac anomalies is small but should guide clinicians not to consider fluoxetine or paroxetine the first option when prescribing selective serotonin reuptake inhibitors to women planning pregnancy. Special attention should be given to alcohol use in pregnant women using selective serotonin reuptake inhibitors. LEVEL OF EVIDENCE: II

1 December 2005 in Obstetrics & Gynecology
Verified
Journal Article
Closed access
HMHeli Malm
Heli Malm
TKTimo Klaukka
Timo Klaukka
PNPertti J. Neuvonen
Pertti J. Neuvonen
To study the effects of selective serotonin reuptake inhibitors (SSRIs) on pregnancy outcome. We performed a population-based study of women exposed to SSRIs during pregnancy (n = 1782). Data were derived from a national project in Finland, established by 3 governmental organizations. In that project, the Drug Reimbursement Register, the Medical Birth Register, the Register of Congenital Malformations, and the Register of Induced Abortions have been linked. Comparisons were made between women with SSRI purchases to matched controls and between women with purchases in different trimesters. Only singleton pregnancies were included. Primary outcomes were major malformations, preterm birth, small for gestational age, low birth weight, and treatment in neonatal special or intensive care unit. Analyses were based on logistic models. Major malformations were not more common in infants or fetuses of women with first trimester SSRI purchases (n = 1,398) when compared with controls with no drug purchases (P = .4). Of infants born to mothers with SSRI purchases in the 3rd trimester, 15.7% were treated in special or intensive care unit compared with 11.2% of infants exposed only during the 1st trimester (P = .009, adjusted odds ratio 1.6, 95% confidence interval 1.1-2.2). We found no increased risk of preterm birth (< 37 weeks), birth 32 weeks of gestation or less, small for gestational age, or low birth weight in women with purchases in each trimester or during the 2nd and 3rd trimesters when compared with women with only 1st trimester purchases. Use of SSRIs during pregnancy is not independently associated with increased risk of adverse perinatal outcome other than need for treatment in neonatal special or intensive care unit.

1 December 2015 in American Journal of Psychiatry
Verified
Journal Article
Open access
HMHeli Malm
Heli Malm
ASAndre Sourander
Andre Sourander
MGMika Gissler
Mika Gissler
DGDavid Gyllenberg
David Gyllenberg
SHSusanna Hinkka-Yli-Salomäki
Susanna Hinkka-Yli-Salomäki
ABAlan S. Brown
Alan S. Brown
Objective:Using national register data, the authors examined the relationship between prenatal selective serotonin reuptake inhibitor (SSRI) treatment and pregnancy complications, accounting for psychiatric diagnoses related to SSRI use.Method:This was a population-based prospective birth cohort study using national register data. The sampling frame included 845,345 offspring, representing all singleton live births in Finland between 1996 and 2010. Pregnancies were classified as exposed to SSRIs (N=15,729), unexposed to SSRIs but with psychiatric diagnoses (N=9,652), and unexposed to medications and psychiatric diagnoses (N=31,394). Pregnancy outcomes in SSRI users were compared with those in the unexposed groups.Results:Offspring of mothers who received SSRI prescriptions during pregnancy had a lower risk for late preterm birth (odds ratio=0.84, 95% CI=0.74–0.96), for very preterm birth (odds ratio=0.52, 95% CI=0.37–0.74), and for cesarean section (odds ratio=0.70, 95% CI=0.66−0.75) compared with offspri...

19 July 2019 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
JCJill Clayton-Smith
Jill Clayton-Smith
RBRebecca Bromley
Rebecca Bromley
JDJohn Dean
John Dean
HJHubert Journel
Hubert Journel
SOSylvie Odent
Sylvie Odent
PTPeter Turnpenny
Peter Turnpenny
A pattern of major and minor congenital anomalies, facial dysmorphic features, and neurodevelopmental difficulties, including cognitive and social impairments has been reported in some children exposed to sodium valproate (VPA) during pregnancy. Recognition of the increased risks of in utero exposure to VPA for congenital malformations, and for the neurodevelopmental effects in particular, has taken many years but these are now acknowledged following the publication of the outcomes of several prospective studies and registries. As with other teratogens, exposure to VPA can have variable effects, ranging from a characteristic pattern of major malformations and significant intellectual disability to the other end of the continuum, characterised by facial dysmorphism which is often difficult to discern and a more moderate effect on neurodevelopment and general health. It has become clear that some individuals with FVSD have complex needs requiring multidisciplinary care but information regarding management is currently lacking in the medical literature. An expert group was convened by ERN-ITHACA, the European Reference Network for Congenital Malformations and Intellectual Disability comprised of professionals involved in the care of individuals with FVSD and with patient representation. Review of published and unpublished literature concerning management of FVSD was undertaken and the level of evidence from these sources graded. Management recommendations were made based on strength of evidence and consensus expert opinion, in the setting of an expert consensus meeting. These were then refined using an iterative process and wider consultation. Whilst there was strong evidence regarding the increase in risk for major congenital malformations and neurodevelopmental difficulties there was a lack of high level evidence in other areas and in particular in terms of optimal clinical management.. The expert consensus approach facilitated the formulation of management recommendations, based on literature evidence and best practice. The outcome of the review and group discussions leads us to propose the term Fetal Valproate Spectrum Disorder (FVSD) as we feel this better encompasses the broad range of effects seen following VPA exposure in utero. The expert consensus approach can be used to define the best available clinical guidance for the diagnosis and management of rare disorders such as FVSD. FVSD can have medical, developmental and neuropsychological impacts with life-long consequences and affected individuals benefit from the input of a number of different health professionals.

17 April 2003 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
HMHeli Malm
Heli Malm
JMJaana Martikainen
Jaana Martikainen
TKTimo Klaukka
Timo Klaukka
PNPertti J Neuvonen
Pertti J Neuvonen
FSFinnish Register-Based Study
Finnish Register-Based Study